/PRNewswire/ US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D
March 15, 2021 GMT
Logo of VLP Therapeutics
GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and three existing investors in the US (Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ Fund, LLC) for research and development of a cancer treatment vaccine. With this funding, VLPT aims to accelerate the project well underway in the US and move into clinical trials at the earliest date possible.
VLP Therapeutics, Inc. (VLPT) announced that it has named Ms.
Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio.
From December 2014 to January 2021, Ms. Toyoda was a venture capitalist at JAFCO Group in Japan, where she led investments in five biotech/medtech companies at home and abroad, and served on the Boards or as an observer, providing hands-on support for their organization structuring, hiring, business development, fund raising, etc. She also provided business consultation as a specialist at the Medical Innovation Support Office (MEDISO) sponsored by the Japanese Ministry of Health, Labor and Welfare, and assistance with technology transfer as a project promoter of the STart-ups from Advanced Research and Technology (START) Program sponsored by the Japan Science and Technology Agenc
Published: Mar 15, 2021
VLP Therapeutics, Inc. (VLPT) announced that it has named Ms.
Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio.
Miwa s incredible skillset and experience will help expedite our vaccine projects and put the technologies to use.
From December 2014 to January 2021, Ms. Toyoda was a venture capitalist at JAFCO Group in Japan, where she led investments in five biotech/medtech companies at home and abroad, and served on the Boards or as an observer, providing hands-on support for their organization structuring, hiring, business development, fund raising, etc. She also provided business consultation as a specialist at the Medical Innovation Support Office (MEDISO) sponsored by the Japanese Ministry of Health, Labor and Welfare, and assistance with technology transfe